Zheng Quan Zhi Xing·2025-08-08 09:20Summary of Key Points Core Viewpoint - The company, Shanghai Medicy Bio-pharmaceutical Co., Ltd., is utilizing part of its idle raised funds for cash management to enhance fund efficiency and generate additional income while ensuring the safety of the funds and not affecting the ongoing investment projects [1][8]. Group 1: Fundraising Overview - The total amount raised by the company as of August 4, 2023, is RMB 1 billion, with a net amount of RMB 985.29 million after deducting underwriting fees [1]. - The funds are stored in a special account, and a tripartite agreement has been signed to regulate the management of these funds [2]. Group 2: Investment Project Details - The net amount raised will be allocated to specific projects, including the establishment of a biopharmaceutical innovation industrial base and laboratory expansion for drug discovery and pharmaceutical research [2]. - The total planned investment for these projects is RMB 2.176 billion, with the adjusted amount from the raised funds being RMB 216 million [2]. Group 3: Cash Management Strategy - The company plans to use up to RMB 400 million of the temporarily idle funds for cash management, ensuring that this does not impact the ongoing projects [4][7]. - The cash management products will include safe and liquid investments such as principal-protected wealth management products, structured deposits, and time deposits [4][6]. Group 4: Decision-Making and Oversight - The board of directors has authorized the management to make investment decisions within the set limits and timeframes, with the finance department responsible for implementation [4][6]. - The company will adhere to disclosure obligations and ensure that the cash management does not alter the intended use of the raised funds [5][8]. Group 5: Monitoring and Compliance - The supervisory board supports the cash management initiative, stating it aligns with regulations and benefits the company and shareholders [7]. - The sponsor institution has confirmed that the cash management plan complies with relevant regulations and does not affect the normal execution of investment projects [8].